Patent classifications
C07F9/02
Preparation of purified phosphorodiamidite
The instant invention relates to a method of phosphorodiamidite production that comprises: (E1) preparing a purified solution of a dialkylamine in a polar solvent as follows: the dialkylamine dissolved in a polar solvent is contacted with a quantity of phosphorus trihalide that is sufficient to react with the alcohol impurities contained in the dialkylamine but sufficiently low to leave a major part of the dialkylamine unreacted, whereby a mixture is obtained that contains the dialkylamine in the polar solvent and reaction products of the impurities with the phosphorous trihalide; the unreacted dialkylamine and polar solvent present in the mixture obtained in step (E1.1.) are extracted from the solution S by their difference of volatility, typically by distillation, whereby the purified solution of the dialkylamine in the polar solvent is obtained; (E2) the purified solution of dialkylamine in a polar solvent as obtained in step (E1) is reacted with a phosphorus trihalide, whereby an intermediate compound is formed; (E3) the intermediate compound obtained in step (E2) is reacted with a hydroxyalkyl compound in the presence of a non-polar co-solvent.
Phosphonium compound, preparation method thereof, epoxy resin composition including the same, and semiconductor device prepared by using the same
A phosphonium compound, a method of preparing the same, an epoxy resin composition including the same, and a semiconductor device encapsulated with the same, the compound being represented by Formula 1: ##STR00001##
CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE
Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.
ELECTROLYTE SOLUTION FOR NON-AQUEOUS ELECTROLYTE BATTERY, AND NON-AQUEOUS ELECTROLYTE BATTERY USING THE SAME
The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at 30 C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50 C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises a non-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound.
Si(R.sup.1).sub.a(R.sup.2).sub.4-a(1)
##STR00001##
Synthesis Process of X-IPM, Stable Crystal Form and Application Thereof
The present application relates to a new method for synthesizing isophosphoramide nitrogen mustard (X-IPM) that is suitable for industrialized production, involves fewer types of solvents, and leads to stable products with high yield. This method is charazterized mainly by the batchwise addition of M (e.g., M is R.sub.3N with R being ethyl; i.e., M is triethylamine) and the specific post-reaction treatment, which make it possible for the reaction to fully proceed, lead to products with less impurities, high yield and relatively stable properties, and can lead to stable crystallized substances with specific crystal structures. The present application also relates to stable crystal forms of the isophosphoramide nitrogen mustard (X-IPM) prepared by the aforementioned method, and use of the same as reactants for the synthesis of aziridine structure-containing compounds.
ALUMINUM DIETHYLPHOSPHINATE CRYSTAL WITH LOW FINE POWDER CONTENT, PREPARATION METHOD THEREFOR AND USE THEREOF
Disclosed are an aluminum diethylphosphinate crystal with a low fine powder content, a preparation method therefor and use thereof in flame retardance of glass fiber-reinforced engineering plastics. In the present invention, a phosphorus-containing aluminum salt complex is used as a seed crystal and is added in a crystallization process of preparing aluminum diethylphosphinate, such that the crystallization process can be effectively regulated and controlled, aluminum diethylphosphinate crystal particles with a low fine powder content, narrow distribution and a large particle size can be obtained, and the problems that the existing aluminum diethylphosphinate powder is prone to bridging, unsmooth feeding and the like can be solved. The present application is applicable to a processing technology of halogen-free flame retardant glass fiber-reinforced engineering plastics. The prepared aluminum diethylphosphinate includes a small amount of phosphorus-containing aluminum salt complex seed crystals, and the flame retardant property of the aluminum diethylphosphinate is not affected.
Process for reducing the chlorine content of organomonophosphites using two solutions
Process with universal usefulness for reducing the chlorine content of organomonophosphites, using two solutions.
System for controlling the reactivity of boronic acids
A protected organoboronic acid includes a boron having an sp.sup.3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp.sup.3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.
Salts and prodrugs of 1-methyl-D-tryptophan
Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.
Borates for photoactivated chemical bleaching
A borate compound for use as photoinduced chemical bleaching reagent is disclosed having improved bleaching performance under certain conditions, compared to neutral borates. The compounds are comprised of Formula I;
R.sub.1R.sub.2R.sub.3R.sub.4BX.sub.a I
where each R.sub.1, R.sub.2, and R.sub.3 and R.sub.4 is, independently, an alkyl, alkylaryl, or arylalkyl, with the proviso that at least one of R.sub.1, R.sub.2, and R.sub.3 and R.sub.4 is an alkyl group and at least two of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 group is positively charged; X is an anion; and a equals 1, 2, or 3.